Marketing authorisation for a medicine Medical devices Application for general reimbursement Inspection of pharmaceutical companies Company authorisations and registrations DKMAnet Clinical trials of medicines Fees Product defects and withdrawals
Theme

Strategy for the DKMA

The Danish Medicines Agency has formulated a strategy for 2022-26. The strategy emphasizes a vision of leading the way in national and international cooperation, and in the dialogue with citizens and society. Read more.

Go to theme
Theme

Vaccines and medicines against COVID-19

Read about the current studies and development of vaccines and medicines for treatment of COVID-19, and how medicines can be approved much quicker in extraordinary situations, if patient safety is sufficiently assured.

Go to theme

News and notifications

Status for the project regarding the control of anti-tampering devices (ATD) on medicinal product packages

25 April 2024

Information for marketing authorisation holders (MAH). The Danish Medicines Agency's laboratory is currently working on a project to check the anti-tampering device (ATD) on selected medicinal product packages. Approx. 10% of the packages requisitioned so far had an ATD that did not work. The flawed devices are designed as a sticker, that can be removed without it being visible on the packaging. We encourage marketing authorisation holders to test their ATDs to avoid unauthorised access to the medicinal products.

Survey on strategy for Ph. Eur. quality standards for monoclonal antibodies

11 March 2024

Continued control of companies' uploading of leaflets to the Danish Medicines Agency's portal DKMAnet

01 February 2024

First electronic product information published for medicines

09 November 2023